Improving antibody drug development using bionanotechnology

Monoclonal antibodies are being used to treat a remarkable breadth of human disorders. Nevertheless, there are several key challenges at the earliest stages of antibody drug development that need to be addressed using simple and widely accessible methods, especially related to generating antibodies against membrane proteins and identifying antibody candidates with drug-like biophysical properties (high solubility and low viscosity). Here we highlight key bionanotechnologies for preparing functional and stable membrane proteins in diverse types of lipoparticles that are being used to improve antibody discovery and engineering efforts. We also highlight key bionanotechnologies for high-throughput and ultra-dilute screening of antibody biophysical properties during antibody discovery and optimization that are being used for identifying antibodies with superior combinations of in vitro (formulation) and in vivo (half-life) properties.

Automated summary

Monoclonal antibodies are widely used in the treatment of various human disorders. However, there are challenges in the early stages of antibody drug development, particularly in generating antibodies against membrane proteins and identifying antibodies with drug-like biophysical properties. This article highlights bionanotechnologies for preparing functional membrane proteins and screening antibody biophysical properties, which can improve antibody discovery and engineering efforts.